Młynarska, E.; Hossa, K.; Krupińska, N.; Pietruszewska, H.; Przybylak, A.; Włudyka, K.; Rysz, J.; Franczyk, B.
Atrial Fibrillation in COVID-19: Mechanisms, Clinical Impact, and Monitoring Strategies. Biomedicines 2025, 13, 2889.
https://doi.org/10.3390/biomedicines13122889
AMA Style
Młynarska E, Hossa K, Krupińska N, Pietruszewska H, Przybylak A, Włudyka K, Rysz J, Franczyk B.
Atrial Fibrillation in COVID-19: Mechanisms, Clinical Impact, and Monitoring Strategies. Biomedicines. 2025; 13(12):2889.
https://doi.org/10.3390/biomedicines13122889
Chicago/Turabian Style
Młynarska, Ewelina, Katarzyna Hossa, Natalia Krupińska, Hanna Pietruszewska, Aleksandra Przybylak, Kinga Włudyka, Jacek Rysz, and Beata Franczyk.
2025. "Atrial Fibrillation in COVID-19: Mechanisms, Clinical Impact, and Monitoring Strategies" Biomedicines 13, no. 12: 2889.
https://doi.org/10.3390/biomedicines13122889
APA Style
Młynarska, E., Hossa, K., Krupińska, N., Pietruszewska, H., Przybylak, A., Włudyka, K., Rysz, J., & Franczyk, B.
(2025). Atrial Fibrillation in COVID-19: Mechanisms, Clinical Impact, and Monitoring Strategies. Biomedicines, 13(12), 2889.
https://doi.org/10.3390/biomedicines13122889